Published in:
01-02-2015 | Pros and Cons in Endocrine Practice
The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: Cons
Authors:
Alexander T. Faje, Anne Klibanski
Published in:
Endocrine
|
Issue 1/2015
Login to get access
Excerpt
The lifetime prevalence of dopamine agonist-treated hyperprolactinemia in women is estimated to be approximately 0.1 %. The incidence peaks in women during early adulthood and declines sharply with advancing age [
1]. Women with symptomatic hyperprolactinemia can experience infertility, oligo-amenorrhea, galactorrhea, acne, or hirsutism. These symptoms or the presence of a prolactin-secreting pituitary macroadenoma (>10 mm) or enlarging microprolactinoma are the generally accepted indications for treatment. …